Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

1.62
-0.0700-4.14%
Post-market: 1.650.0250+1.54%19:57 EDT
Volume:800.95K
Turnover:1.30M
Market Cap:36.71M
PE:-0.12
High:1.68
Open:1.68
Low:1.60
Close:1.69
52wk High:10.99
52wk Low:1.60
Shares:22.66M
Float Shares:15.77M
Volume Ratio:0.90
T/O Rate:5.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0816
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-47.61%
PB:-0.11
PE(LYR):-0.09

Loading ...

Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 04

Top Midday Decliners

MT Newswires Live
·
Aug 01

Karyopharm price target lowered to $11 from $14 at Jefferies

TIPRANKS
·
Jul 31

Analysts Conflicted on These Healthcare Names: Karyopharm Therapeutics (KPTI), Baxter International (BAX) and Alnylam Pharma (ALNY)

TIPRANKS
·
Jul 31

Baird Downgrades Karyopharm Therapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $15

MT Newswires Live
·
Jul 31

Karyopharm Therapeutics Cut to Neutral from Buy by HC Wainwright & Co.

Dow Jones
·
Jul 31

Karyopharm downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
Jul 31

Karyopharm Therapeutics, Inc. : H.c. Wainwright Raises to Neutral from Buy

THOMSON REUTERS
·
Jul 31

Karyopharm downgraded to Neutral from Outperform at Baird

TIPRANKS
·
Jul 31

Premarket Movers | KPTI Plunged 67% as the XPORT-EC-042 Trial Failed to Hit Primary Endpoint

Tiger Newspress
·
Jul 31

Karyopharm Therapeutics Inc : Baird Cuts to Neutral Rating; Cuts Target Price to $3 from $15

THOMSON REUTERS
·
Jul 31

Karyopharm down 69% after XPORT-EC-042 trial did not meet primary endpoint

TIPRANKS
·
Jul 31

Karyopharm to submit sNDA for selinexor plus ruxolitinib

TIPRANKS
·
Jul 31

Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint

TIPRANKS
·
Jul 31

Karyopharm trading resumes

TIPRANKS
·
Jul 31

Karyopharm Plans to Submit Snda for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

THOMSON REUTERS
·
Jul 31

Karyopharm Therapeutics - to Request Priority Review with Snda Submission for Selinexor Plus Ruxolitinib

THOMSON REUTERS
·
Jul 31

Karyopharm Plans August sNDA Filing Seeking FDA Priority Review for Selinexor-ruxolitinib in Myelofibrosis

Reuters
·
Jul 31

Karyopharm Says Phase 3 Selinexor Maintenance Trial in Endometrial Cancer Misses PFS Endpoint

Reuters
·
Jul 31

Karyopharm Therapeutics - no New Safety Signals Observed for Selinexor in Phase 3 Trial

THOMSON REUTERS
·
Jul 31